HEM Pharma Inc. (KOSDAQ:376270)

HEM Pharma Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec 31, 2025	Dec 31, 2024
Operating Revenue	12,979	15,067
Other Revenue	-	-0
Revenue	12,979	15,067
Revenue Growth (YoY)	-13.86%	-
Cost of Revenue	12,355	13,452
Gross Profit	624.02	1,616
Selling, General & Admin	11,483	5,566
Research & Development	3,840	3,212
Amortization of Goodwill & Intangibles	321.92	183.63
Other Operating Expenses	167.28	107.99
Operating Expenses	16,207	9,297
Operating Income	-15,583	-7,682
Interest Expense	-649.13	-261.78
Interest & Investment Income	308.57	232.77
Currency Exchange Gain (Loss)	-8.03	43.26
Other Non Operating Income (Expenses)	-7,277	31.82
EBT Excluding Unusual Items	-23,209	-7,636
Gain (Loss) on Sale of Investments	30.47	24.89
Gain (Loss) on Sale of Assets	-7.02	-
Asset Writedown	-534.93	-
Pretax Income	-23,720	-7,611
Income Tax Expense	3.62	35.34
Earnings From Continuing Operations	-23,724	-7,646
Minority Interest in Earnings	-118.36	-
Net Income	-23,842	-7,646
Net Income to Common	-23,842	-7,646
Shares Outstanding (Basic)	7	6
Shares Outstanding (Diluted)	7	6
Shares Change (YoY)	10.69%	-
EPS (Basic)	-3389.00	-1203.00
EPS (Diluted)	-3389.00	-1203.00
Free Cash Flow	-18,100	-12,367
Free Cash Flow Per Share	-2572.76	-1945.77
Gross Margin	4.81%	10.72%
Operating Margin	-120.06%	-50.98%
Profit Margin	-183.69%	-50.75%
Free Cash Flow Margin	-139.45%	-82.08%
EBITDA	-12,989	-5,259
EBITDA Margin	-100.07%	-34.91%
D&A For EBITDA	2,595	2,422
EBIT	-15,583	-7,682
EBIT Margin	-120.06%	-50.98%
Advertising Expenses	3,163	51.21

Source: S&P Global Market Intelligence. Standard template. Financial Sources.